Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma Academic Article Article uri icon


MeSH Major

  • Antibodies, Monoclonal
  • Lymphoma, Non-Hodgkin


  • Sixteen patients with resistant non-Hodgkin's lymphoma were treated with continuous infusions of vincristine (1-2 mg/m2 daily X 2 days) and bleomycin (0.25 mg/kg bolus dose, then 0.25 mg/kg/daily X 5 days). Responding patients received high dose methotrexate (1500 mg/m2) with citrovorum rescue on days 15, 22, 29, 36. Treatment cycles were repeated every six weeks in responding patients. The response frequency was 50% (three complete and five partial responses). Median response duration was 29 weeks. Major toxicity included stomatitis (63%) and leukopenia (44%). One episode each of possible hypersensitivity pneumonitis and paralytic ileus occurred. Continuous infusions of vincristine and bleomycin should be studied further in less critically ill patients.

publication date

  • January 1982



  • Academic Article


PubMed ID

  • 6180819

Additional Document Info

start page

  • 1690

end page

  • 4


  • 50


  • 9